Stock Track | ImmunityBio Plummets 5.93% Intraday as Q1 Losses Far Exceed Analyst Expectations

Stock Track

May 12

ImmunityBio, Inc. (NASDAQ: IBRX) saw its stock price plummet 5.93% during intraday trading on Monday, as investors reacted negatively to the company's first-quarter financial results.

The biotechnology company reported a quarterly loss per share of $0.62, which significantly exceeded the analyst consensus estimate of a $0.07 loss. This represents a year-over-year loss expansion of over 313%. While the company's revenue showed strong growth, increasing 167.6% to $44.21 million and surpassing expectations of $43.07 million, the market's focus shifted to the substantial widening of losses.

Analysts have increased their loss per share estimates for the coming year following the earnings report, highlighting ongoing concerns about the company's path to profitability. The adjusted loss of 8 cents per share also missed the mean analyst expectation of a 7 cent loss, contributing to the negative investor sentiment during the trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1130629399"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1130629399\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1130629399?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 01:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130629399","market":"hk","top_or_hot":-1,"title":"Stock Track | ImmunityBio Plummets 5.93% Intraday as Q1 Losses Far Exceed Analyst Expectations","media":"Stock Track","content":"<p>ImmunityBio, Inc. (NASDAQ: IBRX) saw its stock price plummet 5.93% during intraday trading on Monday, as investors reacted negatively to the company's first-quarter financial results.</p><p>The biotechnology company reported a quarterly loss per share of $0.62, which significantly exceeded the analyst consensus estimate of a $0.07 loss. This represents a year-over-year loss expansion of over 313%. While the company's revenue showed strong growth, increasing 167.6% to $44.21 million and surpassing expectations of $43.07 million, the market's focus shifted to the substantial widening of losses.</p><p>Analysts have increased their loss per share estimates for the coming year following the earnings report, highlighting ongoing concerns about the company's path to profitability. The adjusted loss of 8 cents per share also missed the mean analyst expectation of a 7 cent loss, contributing to the negative investor sentiment during the trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ImmunityBio Plummets 5.93% Intraday as Q1 Losses Far Exceed Analyst Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ImmunityBio Plummets 5.93% Intraday as Q1 Losses Far Exceed Analyst Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-12 01:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ImmunityBio, Inc. (NASDAQ: IBRX) saw its stock price plummet 5.93% during intraday trading on Monday, as investors reacted negatively to the company's first-quarter financial results.</p><p>The biotechnology company reported a quarterly loss per share of $0.62, which significantly exceeded the analyst consensus estimate of a $0.07 loss. This represents a year-over-year loss expansion of over 313%. While the company's revenue showed strong growth, increasing 167.6% to $44.21 million and surpassing expectations of $43.07 million, the market's focus shifted to the substantial widening of losses.</p><p>Analysts have increased their loss per share estimates for the coming year following the earnings report, highlighting ongoing concerns about the company's path to profitability. The adjusted loss of 8 cents per share also missed the mean analyst expectation of a 7 cent loss, contributing to the negative investor sentiment during the trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1130629399","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130629399","pubTimestamp":1778520713,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ImmunityBio, Inc. (NASDAQ: IBRX) saw its stock price plummet 5.93% during intraday trading on Monday, as investors reacted negatively to the company's first-quarter financial results.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"个股追踪|ImmunityBio盘中暴跌5.93%Q1亏损远超分析师预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"ImmunityBio, Inc. (NASDAQ: IBRX) saw its stock price plummet 5.93% during intraday trading on Monday, as investors reacted negatively to the company's first-quarter financial results.The biotechnology company reported a quarterly loss per share of $0.62, which significantly exceeded the analyst consensus estimate of a $0.07 loss. This represents a year-over-year loss expansion of over 313%. While the company's revenue showed strong growth, increasing 167.6% to $44.21 million and surpassing expectations of $43.07 million, the market's focus shifted to the substantial widening of losses.Analysts have increased their loss per share estimates for the coming year following the earnings report, highlighting ongoing concerns about the company's path to profitability. The adjusted loss of 8 cents per share also missed the mean analyst expectation of a 7 cent loss, contributing to the negative investor sentiment during the trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}